

Signant SmartSignals® Solutions for Alzheimer's and Dementia

MAKING STRIDES TOWARDS NEW TREATMENTS **ONE ENDPOINT AT A TIME**

Alzheimer's Disease (AD) and Dementia studies are notoriously complex, long, and suffer high failure rates, but research is critical in the continued effort to identify disease-modifying treatments. Signant Health can apply decades of direct experience, deep expertise, and innovative clinical trial technologies within our SmartSignals® platform to help researchers detect signal while increasing the quality and reliability of data generated.

IMPROVE ENDPOINT RELIABILITY

SmartSignals eCOA includes electronic versions of common AD and Dementia study scales such as ADAS-Cog and MMSE, as well as built-in internal logic, preset workflows, edit checks, and audio/video recording capabilities. These features optimize scoring accuracy and consistency, and when used in conjunction with our PureSignal Analytics, published data show a significant reduction in errors as well as increased ClinRO and endpoint data reliability.

MAXIMIZE RATER ACCURACY

AD and Dementia studies rely heavily on clinician-rated outcome assessments. With Signant's Rater Training and Central Ratings solutions, our dementia experts will qualify, train, and certify raters for your studies. Through independent reviews and data quality monitoring, we can identify errors and recalibrate raters as needed throughout the course of a study to ensure data validity.

MONITOR & MITIGATE RISKS TO DATA QUALITY

Reliable and accurate data is the cornerstone to any successful clinical trial but especially vital in Alzheimer's studies which suffer extremely high failure rates. Our PureSignal Analytics solution is proven to improve endpoint reliability by helping to identify, correct, and prevent common issues such as errors, bias, or fraud.

ENGAGE AND RETAIN PATIENTS IN LONG-TERM FOLLOW UP STUDIES

Participating in clinical trials can be difficult for people living with Alzheimer's or Dementia. Signant's eConsent solutions simplify home-based consent, while our Telemedicine solution helps support patients and their caregivers/study partners during long-term follow up studies, improving retention in these critical phases.

LEVERAGE OUR RENOWNED AD EXPERTS

Signant is globally recognized as a leader in Alzheimer's trial optimization. Our renowned, in-house experts have supported successful trials that led to regulatory approval of the first new treatments for Alzheimer's in decades. Extensive scientific, operational, technical, and regulatory expertise can be applied to your trials to optimize opportunities for success.

COMMON LIBRARY MEASURES USED IN ALZHEIMER'S AND DEMENTIA CLINICAL TRIALS

- ADAS-COG
- MMSE
- CDR
- RBANS
- ADCS-ADL

ASK US FOR A COMPLETE LIST.

Signant's end-to-end suite of evidence generation solutions and accompanying Alzheimer's and Dementia clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data to improve the probability of study success.

SIGNANT'S ALZHEIMER'S DISEASE AND DEMENTIA CLINICAL TRIAL EXPERIENCE BY THE NUMBERS



I - IV
PHASES



220
TRIALS



16,000
SITES



107,000
PATIENTS



41
COUNTRIES



50
LANGUAGES

DRIVE BETTER RESEARCH OUTCOMES WITH **SIGNANT SMARTSIGNALS® SOLUTIONS**

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.



**ELECTRONIC
CLINICIAN RATINGS**

[LEARN MORE →](#)



**RATER TRAINING
& QUALIFICATION**

[LEARN MORE →](#)



eCONSENT

[LEARN MORE →](#)



TELEMEDICINE

[LEARN MORE →](#)



**PURESIGNAL
ANALYTICS**

[LEARN MORE →](#)




ADVISORY

[LEARN MORE →](#)

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)